Astrazeneca PLC 6-K, filed Mar 30, 2023
Astrazeneca PLC (AZN)
6-K
2023-03-30
For: 2023-03-30
View Original
Added on
April 02, 2026
About this 6-K
Astrazeneca PLC filed this 6-K on March 30, 2023.
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of March 2023
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AstraZeneca completes KYM agreement for CMG901
30 March 2023 07:00 BST
License agreement with KYM Biosciences for CMG901, a Claudin-18.2
antibody drug conjugate, completed
AstraZeneca has completed an exclusive global license
agreement with KYM
Biosciences Inc.i for
CMG901, a potential first-in-class antibody drug conjugate (ADC)
targeting Claudin 18.2, a promising therapeutic target in gastric
cancers.
CMG901 is currently being evaluated in a Phase I trial for the
treatment of Claudin 18.2-positive solid tumours, including gastric
cancer. Preliminary results from the trial have shown an
encouraging profile for CMG901, with early signs of anti-tumour
activity across the dose levels tested.
Financial considerations
AstraZeneca has entered into an exclusive global license for the
research, development, manufacture and commercialisation of CMG901
for an upfront payment of $63m, with potential development and
sales-related milestone payments of up to $1.1bn and tiered
royalties up to low double digits.
The transaction does not impact AstraZeneca's financial guidance
for 2023.
i. KYM Biosciences is a joint venture established by affiliates of
Keymed Biosciences and Lepu Biopharma.
Notes
CMG901
CMG901 is a novel antibody drug conjugate targeting Claudin 18.2,
and consists of an anti-Claudin 18.2 monoclonal antibody, a
protease-degradable linker, and a cytotoxic small molecule
monomethyl auristatin E (MMAE). CMG901 is being developed for the
treatment of solid tumours that express the cell surface protein
Claudin 18.2, including gastric cancers. CMG901 is owned by KYM
Biosciences Inc. (KYM), a joint venture established by affiliates
of Keymed Biosciences (70% of KYM ownership) and Lepu Biopharma
(30% of KYM ownership).
AstraZeneca in gastrointestinal cancers
AstraZeneca has a broad development programme for the treatment of
gastrointestinal (GI) cancers across several medicines and a
variety of tumour types and stages of disease. In 2020, GI cancers
collectively represented approximately 5.1 million new cancer cases
leading to approximately 3.6 million deaths.1
Within this programme, the Company is committed to improving
outcomes in gastric, liver, biliary tract, oesophageal, pancreatic
and colorectal cancers.
Imfinzi (durvalumab) is approved in the US in combination
with chemotherapy (gemcitabine plus cisplatin) for advanced biliary
tract cancer and in combination with Imjudo in unresectable hepatocellular
carcinoma. Imfinzi is being assessed in combinations,
including with Imjudo in liver, oesophageal and gastric
cancers in an extensive development programme spanning early to
late-stage disease across settings.
Enhertu (trastuzumab deruxtecan), a HER2-directed antibody
drug conjugate, is approved in HER2-positive advanced gastric
cancer and is being assessed in colorectal
cancer. Enhertu is jointly developed and commercialised by
AstraZeneca and Daiichi Sankyo.
Lynparza (olaparib), a first-in-class PARP inhibitor, is
approved in BRCA-mutated metastatic pancreatic cancer. Lynparza is
developed and commercialised in collaboration with MSD (Merck &
Co., Inc. inside the US and Canada).
AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the ambition
to provide cures for cancer in every form, following the science to
understand cancer and all its complexities to discover, develop and
deliver life-changing medicines to patients.
The Company's focus is on some of the most challenging cancers. It
is through persistent innovation that AstraZeneca has built one of
the most diverse portfolios and pipelines in the industry, with the
potential to catalyse changes in the practice of medicine and
transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day,
eliminate cancer as a cause of death.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
References
1. World Health Organization. World Cancer Fact Sheet. Available
at: https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf.
Accessed March 2023.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date:
30 March 2023
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|